Table 4.
Complications, treatments and outcomes of older patients with COVID-19.
| All patients (n = 312) | Non-severe (n = 207) | Severe (n = 105) | p value | |
|---|---|---|---|---|
| Complications | ||||
| Acute respiratory distress syndrome, n(%) | 111(35.6) | 18(8.70) | 93(88.6) | 0.041 |
| Shock, n(%) | 76(24.4) | 10(4.83) | 66(62.9) | 0.027 |
| Acute kidney injury, n(%) | 50(16.0) | 7(3.38) | 43(41.0) | 0.004 |
| Acute cardiac injury, n(%) | 103(33.0) | 37(17.9) | 66(62.9) | 0.038 |
| Coagulation disorders, n(%) | 96(30.8) | 66(31.9) | 30(28.6) | 0.645 |
| Nosocomial infection, n(%) | 18(5.77) | 4(1.93) | 14(13.3) | 0.009 |
| Treatments | ||||
| Antiviral therapy, n(%) | 286(91.7) | 186(89.9) | 100(95.2) | 0.426 |
| Antibacterial therapy, n(%) | 87(27.9) | 16(15.2) | 71(67.6) | 0.031 |
| Systemic glucocorticoids, n(%) | 136(43.6) | 68(32.9) | 68(64.8) | 0.046 |
| Immune globulin, n(%) | 165(52.9) | 70(33.8) | 95(90.5) | 0.035 |
| High-flow nasal cannula, n(%) | 94(30.1) | 83(40.1) | 11(10.5) | 0.029 |
| Noninvasive ventilation, n(%) | 22(7.05) | 2(0.966) | 20(19.0) | <0.001 |
| Invasive ventilation, n(%) | 68(21.8) | 0 | 68(64.8) | <0.001 |
| Extracorporeal membrane oxygenation, n(%) | 6(1.92) | 0 | 6(5.71) | <0.001 |
| Continuous renal replacement therapy, n(%) | 24(7.69) | 0 | 24(22.9) | <0.001 |
| Outcomes | 0.010 | |||
| Discharge, n(%) | 245(78.5) | 193(93.2) | 52(49.5) | |
| Hospitalization, n(%) | 46(14.7) | 11(5.31) | 35(33.3) | |
| Death, n(%) | 21(6.73) | 3(0.962) | 18(17.1) |